GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLY) » Definitions » FCF Yield %

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) FCF Yield % : 4.76 (As of May. 16, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Clinuvel Pharmaceuticals's Trailing 12-Month Free Cash Flow is $24.35 Mil, and Market Cap is $511.02 Mil. Therefore, Clinuvel Pharmaceuticals's FCF Yield % for today is 4.76%.

The historical rank and industry rank for Clinuvel Pharmaceuticals's FCF Yield % or its related term are showing as below:

CLVLY' s FCF Yield % Range Over the Past 10 Years
Min: -20.65   Med: 1.15   Max: 5.19
Current: 4.76


During the past 13 years, the highest FCF Yield % of Clinuvel Pharmaceuticals was 5.19%. The lowest was -20.65%. And the median was 1.15%.

CLVLY's FCF Yield % is ranked better than
94.92% of 1556 companies
in the Biotechnology industry
Industry Median: -14.305 vs CLVLY: 4.76

Clinuvel Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2023 was 65.34%.


Clinuvel Pharmaceuticals FCF Yield % Historical Data

The historical data trend for Clinuvel Pharmaceuticals's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals FCF Yield % Chart

Clinuvel Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.08 1.06 1.25 5.46 4.07

Clinuvel Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.51 6.14 3.82 3.46 5.09

Competitive Comparison of Clinuvel Pharmaceuticals's FCF Yield %

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clinuvel Pharmaceuticals's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's FCF Yield % falls into.



Clinuvel Pharmaceuticals FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Clinuvel Pharmaceuticals's FCF Yield % for the fiscal year that ended in Jun. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=24.083 / 591.6883425
=4.07%

Clinuvel Pharmaceuticals's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=14.108 * 2 / 554.1573015
=5.09%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clinuvel Pharmaceuticals FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Clinuvel Pharmaceuticals FCF Yield % Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Headlines

From GuruFocus

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 05-10-2022

US FDA Review for SCENESSE® Extended by Three Months

By Marketwired Marketwired 06-03-2019

CLINUVEL Expands Pharmaceutical Portfolio

By Don Li2 Don Li2 11-08-2021

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 05-20-2022

3 High-Performing Stocks

By Alberto Abaterusso Alberto Abaterusso 07-12-2019

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 06-09-2022

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 07-09-2022

US FDA sets PDUFA date for SCENESSE®

By Marketwired Marketwired 01-10-2019

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 06-19-2022

CLINUVEL Opens VALLAURIX R&D Centre In Singapore

By Marketwired Marketwired 08-31-2020